Phase III trial data shows more than half of patients with moderate to severe Crohn's disease treated with risankizumab (Skyrizi®) 360mg achieved clinical remission in a year.
List view / Grid view
Research suggests the increasing R&D investment in and adoption of biologics will drive growth in the global biologics contract development and manufacturing organisation (CDMO) market.
Boehringer Ingelheim and Eli Lilly have received a complete response letter from the US FDA for their sNDA of empagliflozin 2.5mg, an insulin adjunct.
The US FDA has granted Fast Track designation to Jardiance® for the treatment of chronic kidney disease.
The FDA has granted marketing authorisation for Ofev, as the first treatment for patients with chronic fibrosing interstitial lung diseases (ILDs).
Preliminary agenda and speakers announced for LogiPharma, The World’s Leading Pharma Supply Chain Event (21 – 23 April) 2020.
A Phase II trial for an inhaled cystic fibrosis drug, intended for adults and adolescents, has enrolled its first patient.
Ofev, which is under review for the treatment of people with chronic fibrosing interstitial lung diseases (ILDs), has been given Breakthrough Therapy Designation.
Five pharma companies have filed a complaint in Canadian court over new rules intended to lower the price of drugs in the country.
A new report predicts that the global diabetes drug market will rise to US$58.4 billion by 2025.
AbbVie has announced that it has resolved its US HUMIRA (adalimumab) litigation with Boehringer Ingelheim.
Boehringer Ingelheim has announced that the FDA has granted Fast Track designation to nintedanib for the treatment of SSc-ILD...
The FDA has approved a supplemental New Drug Application for Gilotrif for the first-line treatment of patients with metastatic non-small cell lung cancer...
Allan Hillgrove, Member of the Board of Managing Directors with responsibility for the Human Pharma Business Unit at Boehringer Ingelheim, tells EPR about some of his company’s achievements that he is most proud of, and describes how it will face the digital challenge...